InnSight Technology, Inc. — SEC Form D Filing

InnSight Technology, Inc. filed an SEC Form D on July 13, 2026, reporting $1.35M raised in Medical Devices.

Form D filing details

Filing
SEC Form D
Filing date
July 13, 2026
Amount reported
$1.35M
Industry
Medical Devices
Website
https://www.innsightech.com/

What the company does

Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

Patients with dry eye often suffer from under-diagnosis and require multiple doctor visits to receive proper diagnosis. Additionally, a significant portion of diabetic patients do not comply with required annual testing or home sugar monitoring, leading to unmet needs in non-invasive blood sugar control.

Solution

InnSight Technology is developing the OcuCheck™ Biosensor, a point-of-care device designed to provide precise tear fluid analysis. This device offers a quantitative, immediate result of tear fluid proteins for objective measurement of biomarkers to standardize treatment solutions for conditions like dry eye and systemic diseases such as diabetes.

Verdict

This cleared because it presented a tangible, point-of-care device addressing known diagnostic gaps in high-volume patient populations, not because it promised a revolutionary treatment. Investors were implicitly betting on a clear pathway to market adoption through existing clinical infrastructure and a strong differentiation from current subjective or invasive methods. Upside was limited by the inherent regulatory hurdles and the relatively narrow scope of biomarker detection compared to broader diagnostic platforms.

Source: SEC EDGAR Form D filing